FDA gives breakthrough designation for psychedelic treatment

A clinical‐stage biopharmaceutical company that officials said is committed to revolutionizing mental health care by developing new and innovative next‐generation psychedelic‐based treatment options, announced last week that the U.S. Food and Drug Administration (FDA) has granted Breakthrough Therapy Designation (BTD) for an adjunctive psychedelic‐based therapy for the treatment of major depressive disorder (MDD), according to the press release news outlet, Businesswire.